An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
IVERIC bio, Inc. (NASDAQ: ISEE) granted equity-based awards on December 1, 2021, to six newly-hired employees as part of its 2019 Inducement Stock Incentive Plan. The grants include non-statutory stock options for 160,000 shares at an exercise price of $14.12 and 21,000 restricted stock units across three tranches. The stock options have a ten-year term and vest over four years, while the restricted stock units have varying vesting schedules. These grants aim to incentivize employee retention and align compensation with performance.
Positive
Equity-based awards may enhance employee retention and motivation.
The stock options and restricted stock units are structured to align employee interests with company performance.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to six newly-hired, non-executive employees. The inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.
The inducement grants consisted of non-statutory stock options to purchase an aggregate of 160,000 shares of the Company’s common stock and three separate tranches of an aggregate of 21,000 restricted stock units for shares of the Company’s common stock.
The stock options each have an exercise price of $14.12 per share, equal to the closing price of Iveric Bio’s common stock on December 1, 2021. The stock options each have a ten-year term and vest over four years, with 25% of the shares underlying each option vesting on December 1, 2022 and an additional 2.0833% of the shares underlying each option vesting at the end of each successive month thereafter. The grant in the first tranche of 5,000 restricted stock units vests with respect to 25% of the shares underlying the grant on each of December 1, 2022, December 1, 2023, December 1, 2024 and December 1, 2025. The grant in the second tranche of 2,500 restricted stock units vests with respect to 100% of the shares underlying the grant on December 1, 2022. Grants in the third tranche of 13,500 restricted stock units each vest with respect to 50% of the shares underlying the applicable grant on June 1, 2022 and the remaining 50% of the shares underlying the applicable grant on December 1, 2022. The vesting of each grant is subject to the employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.
Iveric Bio Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.
